| 10.7 0.04 (0.38%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.84  |
1-year : | 15 |
| Resists | First : | 11 |
Second : | 12.84 |
| Pivot price | 9.72 |
|||
| Supports | First : | 9.3 |
Second : | 8.25 |
| MAs | MA(5) : | 10.36 |
MA(20) : | 9.49 |
| MA(100) : | 9.75  |
MA(250) : | 10.01 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 84.8 |
| RSI | RSI(14): 65.5 |
|||
| 52-week | High : | 14.27 | Low : | 7.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VIR ] has closed below upper band by 18.6%. Bollinger Bands are 32.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.01 - 11.05 | 11.05 - 11.09 |
| Low: | 10.47 - 10.52 | 10.52 - 10.56 |
| Close: | 10.62 - 10.7 | 10.7 - 10.76 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Thu, 25 Jul 2024
Vir Biotechnology (VIR) to Release Earnings on Thursday - Defense World
Mon, 22 Jul 2024
Mitsubishi UFJ Asset Management Co. Ltd. Has $243,000 Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Sat, 20 Jul 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Mirae Asset Global Investments Co. Ltd. - Defense World
Thu, 18 Jul 2024
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 - Business Wire
Wed, 17 Jul 2024
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis - Seeking Alpha
Wed, 08 May 2024
Analysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 136 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 76.1 (%) |
| Shares Short | 4,760 (K) |
| Shares Short P.Month | 6,020 (K) |
| EPS | -4.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.39 |
| Profit Margin | 0 % |
| Operating Margin | -142.1 % |
| Return on Assets (ttm) | -16.8 % |
| Return on Equity (ttm) | -30.7 % |
| Qtrly Rev. Growth | -10.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.58 |
| EBITDA (p.s.) | -4.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -762 (M) |
| Levered Free Cash Flow | -612 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | -0.5 |
| Price to Book value | 0.93 |
| Price to Sales | 18.28 |
| Price to Cash Flow | -1.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|